KYTX
Kyverna Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.85
−0.68%Price chart
Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29
Key dataOct 29, 2026
Open$5.91
From 52W high−48.00%
Volume844506.00
Market cap$361.78M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 29, 2026
Open
$5.91
From 52W high
−48.00%
Volume
844506.00
Market cap
$361.78M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.3x
P/E (TTM)
—
RSI (14)
44.7
MomentumView details →
1D Return
−0.68%
YTD Return
−37.14%
SummaryUpdated Jun 1, 2026
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Emeryville, California. Originally incorporated as BAIT Therapeutics, Inc., the company changed its name to Kyverna Therapeutics in October 2019. Kyverna went public in February 2024 and focuses on developing innovative cell therapies specifically designed to treat autoimmune diseases, representing a novel approach in a field traditionally dominated by immunosuppressive drugs and biologics.
Similar companies
Latest newsMore news →
Kyverna Therapeutics, Inc. presented one-year registrational data for miv-cel in stiff person syndrome, reporting sustained clinical benefit across all primary and secondary endpoints and that nearly all patients remained off chronic immunotherapies.9d agoKyverna Therapeutics reported positive one-year data showing durable clinical responses and a favorable safety profile for miv-cel in stiff person syndrome and generalized myasthenia gravis.36d agoThe FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Kyverna Therapeutics' miv-cel for the treatment of non-active secondary progressive multiple sclerosis (naSPMS).80d ago